Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-12-05
2000-07-04
Travers, Russell
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
424 854, A61K 3800, A61K 3821
Patent
active
060839198
ABSTRACT:
The subject invention pertains to novel methods for treating autoimmune-related diseases, such as Multiple Sclerosis (MS). One embodiment of the method of the invention comprises administering interleukin-10 (IL-10) and transforming growth factor-beta (TGF-.beta.), in combination, to a person afflicted with or predisposed to an autoimmune disease. When administered in combination, these cytokines act in a synergistic manner as suppressor factors to inhibit the activation of self-reactive T cells that are involved in autoimmune disease.
REFERENCES:
patent: 5650396 (1997-07-01), Canlino et al.
Stevens et al, J of Neuroimmunology (51) pp 77-83, 1994.
Rott et al, Eur J Immunol, vol. 24 pp 1434-40, 1994.
Schluesenen et al, J of Neuroimmulogy vol. 24, pp 249-58, 1989.
Soos et al, J immunology, vol. 155 pp 2747-53, 1995.
Karpus, W.J., Swanborg, R.H. (1991) "CD4+ suppressor cells inhibit the function of effector cells of experimental autoimmune encephalomyelitis through a mechanism involving transforming growth factor-.beta.". Journal of Immunology 146: 1163-1168.
Weckmann, A.L., Alcocer-Varela, J. (1996) "Cytokine Inhibitors in Autoimmune Disease". Seminars in Arthritis and Rheumatism 26(2): 539-557.
Chen, Y. Inobe, J., Weiner, H.L. (1995) "Induction of Oral Tolerance to Myelin Basic Protein in CD8-Depleted Mice". Journal of Immunology 155: 910-916.
Reitamo, S. et al. (1994) "Interleukin 10 up-regulates elastin gene expression in vivo and in vitro at the transcription level". Biochemical Journal 302: 331-333.
Oswald, I.P. et al. (1992) "IL-10 synergizes with IL-4 and transforming growth factor-.beta. to inhibit macrophage cytotoxic activity". Journal of Immunology 148: 3578-3582.
Vieira, P., de Waal Malefyt, R., Dang, M.-N., Johnson, K.E., Kastelein, R., Fiorentino, D.F., de Vries, J.E., Roncarolo, M.-G., Mosmann, T.R., and Moore, K.W. (1991) "Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRF1" Proc. Natl. Acad. Sci. 88:1172.
Zamvil, S.S. and Steinman, L. (1990) "The T lymphocyte in experimental allergic encephalomyelitis" Annu. Rev. Immunol. 8:579-621.
Chaouat, G., Assal-Meliani, A., Martal, J., Raghupathy, R., Elliott, J., Mosmann, T. and Wegmann, T.G. (1995) "IL 10 prevents naturally occurring fetal loss in the CBA X DBA/2 mating combinations, and local defect in IL10 production in this abortion-prone combination is corrected by in vivo injection of IFN.tau." J. Immunol. 154:4261-4268.
Johns, L.T., Flanders, K.C., Ranges, G.E. and Sriram, S. (1991) "Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-.beta.1" J. Immunol. 147:1792-1796.
Johnson, H.M. and Blalock, J.E. (1980) "Interferon immunosuppression: mediation by a suppressor factor" Infect. Immun. 29:301-305.
Massague, J. (1990) "The transforming growth factor-.beta. family" Annu. Rev. Cell. Biol. 6: 597.
Moore, K.W., Vieira, P., Fiorentino, D.F., Trounstine, M.L., Khan, T.A., and Mosmann, T.R., (1990) "Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1" Science 248:1230.
Rott, O., Fleischer, B. and Cash, E. (1994) "Interleukin-10 prevents experimental allergic encephalomyelitis in rats" Eur. J. Immunol 24: 1434-1440.
Schluesener, H.J. and Lider, O. (1989) "Transforming growth factors .beta.1 and .beta.2: Cytokines with identical immunosuppressive effects and potential role in the regulation of autoimmune T cell function" J. Neuroimmunol. 24:249-258.
Soos, J.M., Subramaniam, P.S., Hobeika, A.C., Schiffenbauer, J. and Johnson, H.M. (1995) "The IFN pregnancy recognition hormone, interferon tau, blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity" J. Immunol. 155:2747-2753.
Stevens, D.B., Gould, K.E. and Swanborg, R.H. (1994) "Transforming growth factor-beta 1 inhibits tumor necrosis factor-alpha/lymphotoxin production and adoptive transfer of disease by effector cells of autoimmune encephalomyelitis" J. Neuroimmunol. 51: 77-83.
Johnson Howard M.
Mujtaba Mustafa G.
Soos Jeanne M.
Travers Russell
University of Florida
LandOfFree
Materials and methods for treating autoimmune disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Materials and methods for treating autoimmune disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for treating autoimmune disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1486676